Cargando…

2424. Review of Antimicrobial Susceptibility Profile of Different Nocardia Species, a Tertiary Center Experience

BACKGROUND: Nocardia spp. are ubiquitous Gram-positive weakly acid-fast environmental microorganisms. Although considered an opportunistic infection, approximately 1/3 of the reported infections are in immunocompetent patients. Treatment is usually challenging, prolonged and involves multiple agents...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamdi, Ahmed, Saleh, Omar Abu, Fida, Madiha, Bryson, Alexandra, Wengenack, Nancy L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253928/
http://dx.doi.org/10.1093/ofid/ofy210.2077
_version_ 1783373607229980672
author Hamdi, Ahmed
Saleh, Omar Abu
Fida, Madiha
Bryson, Alexandra
Wengenack, Nancy L
author_facet Hamdi, Ahmed
Saleh, Omar Abu
Fida, Madiha
Bryson, Alexandra
Wengenack, Nancy L
author_sort Hamdi, Ahmed
collection PubMed
description BACKGROUND: Nocardia spp. are ubiquitous Gram-positive weakly acid-fast environmental microorganisms. Although considered an opportunistic infection, approximately 1/3 of the reported infections are in immunocompetent patients. Treatment is usually challenging, prolonged and involves multiple agents depending on the site of infection, clinical syndrome and the immune status of the patient. METHODS: We conducted a retrospective review of clinical samples with positive cultures for Nocardia spp. from 2011 to 2017. Specimens were cultured in MGIT broth or on Middlebrook agar biplates and isolated colony growth was then identified using MALDI-TOF MS or 16S rDNA gene sequencing. Antimicrobial susceptibility testing was performed using the TREK Sensititre Rapid Growing Mycobacteria Plate. RESULTS: We reviewed total of 1,840 samples positive for Nocardia spp. Most commonly isolated species included N. cyriacigeorgica (16.9%), N. nova complex (15.7%), N. farcinica complex (14.8%), N. brasiliensis (11.5%) and N. abscessus complex (8.2%). Susceptibilities of the more common Nocardia species are shown in the graph. Source of the positive cultures was variable with majority (>60%) from pulmonary source (sputum, BAL and lung tissue), blood in 5.7% and brain in 3.6%. Most common Nocardia species isolated from brain specimens were N. farcinica complex (24/59) followed by N. abscessus complex (17/59). Most common Nocardia species isolated from blood were N. farcinica complex (38/99) followed by N. nova complex (22/99) and N. cyriacigeorgica (15/99). CONCLUSION: The antimicrobials that continue to show high activity against most Nocardia species (>95%) are: amikacin, linezolid and TMP/SMX. N. pseudobrasiliensis was noted to have high rates of resistance to TMP/SMX (87%). N. farcinia, N. brasiliensis and N. transvalensis/wallacei complex were >90% susceptible to amoxicillin/clavulanate. Clarithromycin had >99% activity against N. nova complex while both ceftriaxone and doxycycline had> 90% activity against N. abscessus complex. It is crucial to identify Nocardia species and obtain susceptibilities to help better choose the regimen with the best clinical outcome. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253928
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62539282018-11-28 2424. Review of Antimicrobial Susceptibility Profile of Different Nocardia Species, a Tertiary Center Experience Hamdi, Ahmed Saleh, Omar Abu Fida, Madiha Bryson, Alexandra Wengenack, Nancy L Open Forum Infect Dis Abstracts BACKGROUND: Nocardia spp. are ubiquitous Gram-positive weakly acid-fast environmental microorganisms. Although considered an opportunistic infection, approximately 1/3 of the reported infections are in immunocompetent patients. Treatment is usually challenging, prolonged and involves multiple agents depending on the site of infection, clinical syndrome and the immune status of the patient. METHODS: We conducted a retrospective review of clinical samples with positive cultures for Nocardia spp. from 2011 to 2017. Specimens were cultured in MGIT broth or on Middlebrook agar biplates and isolated colony growth was then identified using MALDI-TOF MS or 16S rDNA gene sequencing. Antimicrobial susceptibility testing was performed using the TREK Sensititre Rapid Growing Mycobacteria Plate. RESULTS: We reviewed total of 1,840 samples positive for Nocardia spp. Most commonly isolated species included N. cyriacigeorgica (16.9%), N. nova complex (15.7%), N. farcinica complex (14.8%), N. brasiliensis (11.5%) and N. abscessus complex (8.2%). Susceptibilities of the more common Nocardia species are shown in the graph. Source of the positive cultures was variable with majority (>60%) from pulmonary source (sputum, BAL and lung tissue), blood in 5.7% and brain in 3.6%. Most common Nocardia species isolated from brain specimens were N. farcinica complex (24/59) followed by N. abscessus complex (17/59). Most common Nocardia species isolated from blood were N. farcinica complex (38/99) followed by N. nova complex (22/99) and N. cyriacigeorgica (15/99). CONCLUSION: The antimicrobials that continue to show high activity against most Nocardia species (>95%) are: amikacin, linezolid and TMP/SMX. N. pseudobrasiliensis was noted to have high rates of resistance to TMP/SMX (87%). N. farcinia, N. brasiliensis and N. transvalensis/wallacei complex were >90% susceptible to amoxicillin/clavulanate. Clarithromycin had >99% activity against N. nova complex while both ceftriaxone and doxycycline had> 90% activity against N. abscessus complex. It is crucial to identify Nocardia species and obtain susceptibilities to help better choose the regimen with the best clinical outcome. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253928/ http://dx.doi.org/10.1093/ofid/ofy210.2077 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Hamdi, Ahmed
Saleh, Omar Abu
Fida, Madiha
Bryson, Alexandra
Wengenack, Nancy L
2424. Review of Antimicrobial Susceptibility Profile of Different Nocardia Species, a Tertiary Center Experience
title 2424. Review of Antimicrobial Susceptibility Profile of Different Nocardia Species, a Tertiary Center Experience
title_full 2424. Review of Antimicrobial Susceptibility Profile of Different Nocardia Species, a Tertiary Center Experience
title_fullStr 2424. Review of Antimicrobial Susceptibility Profile of Different Nocardia Species, a Tertiary Center Experience
title_full_unstemmed 2424. Review of Antimicrobial Susceptibility Profile of Different Nocardia Species, a Tertiary Center Experience
title_short 2424. Review of Antimicrobial Susceptibility Profile of Different Nocardia Species, a Tertiary Center Experience
title_sort 2424. review of antimicrobial susceptibility profile of different nocardia species, a tertiary center experience
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253928/
http://dx.doi.org/10.1093/ofid/ofy210.2077
work_keys_str_mv AT hamdiahmed 2424reviewofantimicrobialsusceptibilityprofileofdifferentnocardiaspeciesatertiarycenterexperience
AT salehomarabu 2424reviewofantimicrobialsusceptibilityprofileofdifferentnocardiaspeciesatertiarycenterexperience
AT fidamadiha 2424reviewofantimicrobialsusceptibilityprofileofdifferentnocardiaspeciesatertiarycenterexperience
AT brysonalexandra 2424reviewofantimicrobialsusceptibilityprofileofdifferentnocardiaspeciesatertiarycenterexperience
AT wengenacknancyl 2424reviewofantimicrobialsusceptibilityprofileofdifferentnocardiaspeciesatertiarycenterexperience